Company intelligence / Profile preview

Neurocentria Inc.

Walnut Creek, North Carolina, United Statesneurocentria.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Neurocentria has received FDA approval for pivotal Phase 2b/3 trials for NRCT-101SR in adults with ADHD. Early-stage clinical trials showed the drug addresses ADHD symptoms without side effects, improves mood status in 3-7 days, improves cognition, and produces no reported adverse side effects relative to placebo. The company also has approval for Phase 2b trials for Alzheimer's disease and is seeking approval for Phase 2b/3 trials for late-life depression.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

NRCT-101SR

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neurocentria Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurocentria Inc..

Explore the full profile